Postpartum Depression (PPD) affects between 10-15% of new mothers. PPD causes mothers to suffer from a long-lasting depression that, if severe, can put both the mother and the child in danger. Though PPD is common, available antidepressants are not guaranteed to help. A new treatment, brexanolone, offers hope for some mothers but also has severe side effects.
Read More »Tag: depression
New Warnings on Singulair Allergy and Asthma Drug
Due to its psychiatric side effects, the FDA advises that Singulair should not be the first choice treatment for mild allergies, and healthcare providers should weigh the potential risks and benefits before prescribing Singulair for asthma.
Read More »NCHR’s Public Comments on United States Preventive Services Task Force’s Draft Research Plan on Screening for Depression, Anxiety, and Suicide Risk in Children and Adolescents
We agree that it is very important to examine whether screening programs for depression, anxiety, and increased risk of suicide accurately identify children and adolescents with those conditions, as well as whether screening leads to improved health outcomes among children and adolescents. We agree that it is equally important to assess the potential harms of screening and treatment. There are, however, three points that we suggest should be re-examined in the draft research plan.
Read More »Spravato for suicidal veterans? What we know and don’t know
NCHR Testimony on Singulair and Neuropsychiatric Side Effects
September 27, 2019. Singulair has serious side effects and we need much better data to determine the likely benefit and risk of harm for patients. FDA has an important role to play in encouraging this research. In the meantime, patients, parents, and clinicians must be given clear information about the risks so that they can make an informed decision about whether to use montelukast (Singulair).
Read More »